Drug Therapy for Stable Angina Pectoris.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic review methodology
PubMed 28120185 · doi:10.1007/s40265-017-0691-7
What was done
This narrative review summarizes medical management strategies and drug therapy for chronic stable angina pectoris. The author compares varying international guideline recommendations with an individualized approach tailored to patient circulatory status and specific comorbidities.
What was found
The abstract reports no quantitative outcomes, trial metrics, or numerical effect sizes. It notes that while standard management combines lifestyle changes, anti-anginal drugs, aspirin, and statins, guideline recommendations for selecting initial or combination anti-anginal agents are not firmly evidence-based. In addition, optimal pharmacotherapy for patients with angina and angiographically normal coronary arteries remains undefined.
Why it matters
It highlights limitations in existing guideline algorithms and provides a framework for tailoring anti-anginal pharmacotherapy to individual patient hemodynamics and comorbidities.
Limits
The abstract describes a narrative review with no systematic search methodology, meta-analytic pooling, sample sizes, or original empirical data.
Cited by
- supports Sublingual nitroglycerin rapidly dilates coronary arteries to treat acute angina.